S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

IN8bio Stock Forecast, Price & News

-0.36 (-6.14%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
11,579 shs
Average Volume
32,992 shs
Market Capitalization
$103.15 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive INAB News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

IN8bio logo

About IN8bio

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York.


FY2021 EPS Estimates for IN8bio Inc (NASDAQ:INAB) Lifted by B. Riley
November 15, 2021 |  americanbankingnews.com
IN8bio (NASDAQ:INAB) Announces Earnings Results
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$103.15 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.78 out of 5 stars

Medical Sector

838th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

129th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

IN8bio (NASDAQ:INAB) Frequently Asked Questions

Is IN8bio a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IN8bio stock.
View analyst ratings for IN8bio
or view top-rated stocks.

When is IN8bio's next earnings date?

IN8bio is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for IN8bio

How were IN8bio's earnings last quarter?

IN8bio Inc (NASDAQ:INAB) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.11.
View IN8bio's earnings history

What price target have analysts set for INAB?

2 Wall Street analysts have issued 1-year target prices for IN8bio's shares. Their forecasts range from $12.00 to $19.00. On average, they anticipate IN8bio's stock price to reach $15.50 in the next year. This suggests a possible upside of 181.8% from the stock's current price.
View analysts' price targets for IN8bio
or view top-rated stocks among Wall Street analysts.

When did IN8bio IPO?

(INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.

What is IN8bio's stock symbol?

IN8bio trades on the NASDAQ under the ticker symbol "INAB."

When does the company's lock-up period expire?

IN8bio's lock-up period expires on Wednesday, January 26th. IN8bio had issued 4,000,000 shares in its public offering on July 30th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are IN8bio's major shareholders?

IN8bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital World Investors (4.27%), B. Riley Financial Inc. (1.37%), Voss Capital LLC (0.43%), Tudor Investment Corp Et Al (0.34%) and Millennium Management LLC (0.14%).

Which institutional investors are buying IN8bio stock?

INAB stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, B. Riley Financial Inc., Voss Capital LLC, Tudor Investment Corp Et Al, and Millennium Management LLC.

How do I buy shares of IN8bio?

Shares of INAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IN8bio's stock price today?

One share of INAB stock can currently be purchased for approximately $5.50.

How much money does IN8bio make?

IN8bio has a market capitalization of $103.15 million.

How many employees does IN8bio have?

IN8bio employs 7 workers across the globe.

What is IN8bio's official website?

The official website for IN8bio is www.in8bio.com.

Where are IN8bio's headquarters?

IN8bio is headquartered at 79 Madison Avenue, New York, New York 10016.

How can I contact IN8bio?

IN8bio's mailing address is 79 Madison Avenue, New York, New York 10016. The company can be reached via phone at 646-600-6438.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.